Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has announced US 510(k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH navigation technology, featuring AI-powered algorithms and a verified OEC Open interface with the GE HealthCare OEC 3D mobile CBCT Imaging System.
Robotically-assisted bronchoscopy represents a small but fast-growing segment of lung biopsy procedures in the US. The MONARCH Platform, the first robotically assisted bronchoscopy system to market, provides minimally invasive access to and visualisation of airways to help clinicians biopsy suspicious lung nodules.
Nearly half of early-stage lesions are located in the periphery of the lung, which is difficult to reach with traditional bronchoscopy. The MONARCH Platform can aid clinicians in getting to an early, definitive diagnosis in lung cancer cases, which can help care teams get patients into the treatment pathway an average of three weeks faster.
“Our goal with the MONARCH Platform is to change the treatment paradigm for diseases such as lung cancer, where significant unmet needs still remain,” said Aleksandra Popovic, President, MONARCH, Johnson & Johnson MedTech. “MONARCH QUEST demonstrates our commitment to delivering meaningful innovation that helps clinicians advance the standard of care for their patients.”
